<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074100</url>
  </required_header>
  <id_info>
    <org_study_id>XANTHUS-0001A1-200-GL</org_study_id>
    <secondary_id>MSKCC-03080</secondary_id>
    <secondary_id>CDR0000341687</secondary_id>
    <nct_id>NCT00074100</nct_id>
  </id_info>
  <brief_title>Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy</brief_title>
  <official_title>Amonafide: Individual Phenotype-Adjusted Chemotherapy for Women With Metastatic Breast Cancer Who Have Progressed Despite Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as amonafide, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of amonafide in treating women who have&#xD;
      metastatic breast cancer that has progressed after previous chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the time to progression in women with metastatic breast cancer who have&#xD;
           progressed after prior chemotherapy and are now treated with amonafide.&#xD;
&#xD;
        -  Determine the overall response rate (complete and partial response) in patients treated&#xD;
           with this drug.&#xD;
&#xD;
        -  Determine the safety of a phenotypically driven dosing regimen of this drug in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to tumor response, duration of response, and time to treatment&#xD;
           failure in patients treated with this drug.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive amonafide IV over 1 hour on days 1-5. Treatment repeats every 21 days for at&#xD;
      least 5 courses in the absence of disease progression or unacceptable toxicity. Patients with&#xD;
      stable or responding disease may receive additional courses (beyond 5 courses) at the&#xD;
      investigator's discretion.&#xD;
&#xD;
      Patients are followed at 30 days and then every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 175 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amonafide dihydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic (stage IV) disease&#xD;
&#xD;
          -  Relapsed after 1 of the following prior therapy regimens*:&#xD;
&#xD;
               -  Adjuvant therapy containing an anthracycline and a taxane&#xD;
&#xD;
               -  Adjuvant anthracycline therapy followed by first-line metastatic treatment&#xD;
                  containing a taxane NOTE: *No relapse within 12 months of initiation of prior&#xD;
                  therapy&#xD;
&#xD;
          -  Measurable disease by CT scan or MRI&#xD;
&#xD;
               -  No ascites, pleural effusions, or osteoblastic bone metastases as the only site&#xD;
                  of measurable disease&#xD;
&#xD;
          -  Refractory to hormonal anticancer therapy completed more than 4 weeks before study&#xD;
             therapy&#xD;
&#xD;
          -  HER2/neu positive allowed provided patient received prior trastuzumab (HerceptinÂ®)&#xD;
&#xD;
               -  MUGA or echocardiogram normal while on trastuzumab&#xD;
&#xD;
          -  No known history of or current brain or leptomeningeal metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
          -  No clinically significant abnormal hematological parameters&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN in case of liver&#xD;
             metastases)&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times ULN (5 times ULN in case of liver metastases)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
          -  No cardiac insufficiency&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  LVEF at least 50% OR at least lower limit of normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 4 weeks before, during, and for at&#xD;
             least 4 weeks after study participation&#xD;
&#xD;
          -  No preexisting neuropathy (motor or sensory) greater than grade 2&#xD;
&#xD;
          -  No clinically significant abnormal biochemical parameters&#xD;
&#xD;
          -  No clinically significant active infection&#xD;
&#xD;
          -  No other prior malignancy except cured nonmelanoma skin cancer or curatively treated&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No psychological illness or condition that would preclude study participation&#xD;
&#xD;
          -  No other known condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 months since prior trastuzumab&#xD;
&#xD;
          -  More than 2 weeks since prior growth factor therapy (i.e., filgrastim [G-CSF] or&#xD;
             sargramostim [GM-CSF])&#xD;
&#xD;
          -  No concurrent systemic anticancer immune modulators&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  No concurrent chronic systemic steroids&#xD;
&#xD;
               -  Concurrent topical or inhaled steroids for dermatological or allergy/asthma&#xD;
                  conditions allowed provided therapy was initiated prior to study enrollment&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed provided therapy was initiated prior to&#xD;
             study enrollment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy directed at target lesions&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational new drug&#xD;
&#xD;
          -  More than 2 weeks since prior blood transfusion&#xD;
&#xD;
          -  No other concurrent systemic anticancer agents, including immunosuppressive agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed provided therapy was initiated prior to study&#xD;
             enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford A. Hudis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amonafide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

